12 evaluated patient‐level data from four studies in patients with disease burden varying from Stage II or lower/limited to Stage III or higher/extensive and who had initiated DA at Hb ≤10 g/dL per EMA's summary of product characteristics for DA 5. However, no studies have evaluated the efficacy of DA when initiated at Hb ≤10 g/dL in patients with advanced disease and CIA, to meet the limitations of use for DA in the US; specifically that DA is not for use in patients with cancer receiving myelosuppressive chemotherapy when the anticipated outcome is cure 4. Here, GSTM1 is linked to cancer.